Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16135843 | 0.95 | ALDH1A1 (0.56) | ALDH1A1HRH3PKMLMNAL3MBTL1 | |
| SCHEMBL16135855 | 0.92 | ALDH1A1 (0.57) | ALDH1A1TP53LMNAL3MBTL1KMT2A | |
| SCHEMBL16311199 | 0.92 | ALDH1A1 (0.52) | ALDH1A1TP53PKMLMNAL3MBTL1 | |
| SCHEMBL16311215 | 0.92 | ALDH1A1 (0.52) | ALDH1A1HRH3PKMLMNAL3MBTL1 | |
| SCHEMBL16136147 | 0.91 | ALDH1A1 (0.51) | ALDH1A1HRH3POLBLMNAL3MBTL1 | |
| SCHEMBL16136138 | 0.91 | ALDH1A1 (0.51) | ALDH1A1PKMLMNAL3MBTL1KMT2A | |
| SCHEMBL16111205 | 0.89 | CHRM5 (0.52) | ALDH1A1PKMLMNAL3MBTL1KMT2A | |
| SCHEMBL16136140 | 0.86 | ALDH1A1 (0.50) | ALDH1A1PKMPOLBLMNAL3MBTL1 | |
| SCHEMBL16135837 | 0.84 | ALDH1A1 (0.44) | ALDH1A1POLBLMNAL3MBTL1KMT2A | |
| SCHEMBL16135884 | 0.83 | ALDH1A1 (0.57) | ALDH1A1PKMLMNAL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944603-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944603-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2017-11-02 | — | — | US | disclosed |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-12-18 | — | — | US | disclosed |
| WO-2014160478-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | ALDH1A1 514/4885HRH3 1675/4885TP53 4275/4885 |
| US-20140371238-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | ALDH1A1 514/4885HRH3 1675/4885TP53 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.